(IN BRIEF) GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma. The approval follows positive results from the DREAMM-7 and DREAMM-8 phase III trials, … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged anti-BCMA, antibody-drug conjugate, Blenrep, bortezomib, chemotherapy, clinical efficacy, clinical trials, DREAMM-7, DREAMM-8, global markets, GSK, Japan approval, Multiple Myeloma, oncology, orphan drug designation, overall survival, partnership, PDUFA, pomalidomide, progression-free survival, regulatory approval, sustainability, treatment options
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release
Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, biotechnologie, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Ernennung, F&E, Forschung und Entwicklung, Genome Research, Genomik, GlaxoSmithKline plc, GSK, Immunologie, Imperial College, Infektionskrankheiten, Jemperli, künstliche Intelligenz, maschinelles Lernen, Medikamente, Nucala, Onkologie, Pfizer, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, appointment, artificial-intelligence, biotechnology, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Genome Research, genomics, GlaxoSmithKline plc, GSK, immunology, Imperial College, infectious disease, Jemperli, Machine Learning, medicines, Nucala®, oncology, Pfizer, R&D, research and development, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?